Immunotherapy may have potential as prostate cancer treatment, study shows

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

Clinical Roundup

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

A study led by UCLA investigators shows that AI could play a key role in improving treatment outcomes for patients with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

A new large-scale study, co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators, provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is equally as effective as conventional radiotherapy for prostate cancer, without compromising patient safety.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

A five-year study on subjects who had only the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function.

March 07, 2025

Vol.51 No.09

Black History Month Conversation with The Cancer Letter

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

Nearly 30 years ago, while completing an assignment for his master’s degree in public health, Brian Rivers discovered he had a family history of prostate cancer.

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

February 14, 2025

Vol.51 No.06

Immunotherapy may have potential as prostate cancer treatment, study shows

YOU MAY BE INTERESTED IN

FDA approves prostate cancer imaging agent Gozellix

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Immunotherapy may have potential as prostate cancer treatment, study shows

YOU MAY BE INTERESTED IN

FDA approves prostate cancer imaging agent Gozellix

AI tool helps predict who will benefit from focal therapy for prostate cancer, study shows

Shorter radiation treatment approach shows safety and efficacy for early-stage prostate cancer

Partial gland removal for prostate cancer patients may avoid recurrence, study shows

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America“It gives America, in part, its identity.”

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Never miss an issue!

Login

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”